Ikonisys SA: Successful Study in Collaboration With the Neag Cancer Center of UConn School of Medicine Demonstrates the Power of the Ikoniscope Platform for Detection of Extremely Rare Cells in the Field of Immuno-Oncology
10 Octobre 2023 - 7:30AM
Business Wire
Regulatory News:
Ikonisys SA (ISIN Code: FR00140048X2 / Ticker: ALIKO), a
company specializing in the early and accurate detection of cancer
with a unique fully-automated solution for medical diagnostic labs,
today announces the successful completion of a study, undertaken in
collaboration with the Carole and Ray Neag Comprehensive Cancer
Center of the University of Connecticut (UConn) School of Medicine,
for the detection of extremely rare cells in the field of
immune-oncology with the Ikoniscope 20.
The study thus demonstrates the ability of the Ikoniscope20
platform to detect rare, clinically significant, specific
populations of CD8 T cells, at a sensitivity and frequency higher
than that obtained by flow cytometry, the standard tool used for
such detection, and via other rare cell detection methodologies. In
addition, such a microscopy-based approach provides the ability for
detailed morphological analysis of detected cells of interest.
The project demonstrates the potential superiority of the
Ikoniscope20 automated fluorescence microscopy platform for
accurate enumeration of a cell sub-population of clinical interest
over a more traditional approach such as flow cytometry.
Moving forward, this approach could be applied to the
enumeration of the CD8 cells of interest within the tumor
infiltrating lymphocytes obtained from specific tumor types. More
broadly, this provides a proof of principle that the Ikonisys
platform is fully suited for detection of rare cancer cells in
blood or other body fluids without a need for prior enrichment. It
also demonstrates the ability of the Ikoniscope20 platform to
compete with more costly flow cytometry instruments, and perform
immune monitoring functions more effectively, inexpensively, and
easily, and opens other commercialization opportunities of the
Ikoniscope20, as a tool used by research laboratories for immune
response monitoring.
A manuscript, for publication in a peer-reviewed journal,
reporting the results of the study, is currently in
preparation.
Pramod Srivastava PhD MD, Director of the Neag Cancer
Center, says: “There is a fast-growing need for monitoring the
many experimental and newly approved immunotherapy treatments for
cancer patients, as well as for research studies in animal models.
These results show a new path towards fulfilling that unmet
need.”
Dr. Michael Kilpatrick PhD, Chief Scientific Officer of
Ikonisys, added: “We are very pleased to have been able to
bring to success this project, that provides proof of principle for
the use of our technology also in immuno-oncology. Working with a
leading medical center to further demonstrate the potential of the
Ikoniscope20 platform in the detection and quantification of
clinically relevant immune cells has been an honor and continues to
demonstrate the growing potential of our automated fluorescence
microscopy platform to penetrate new markets.”
About Ikonisys Ikonisys SA is a cell-based diagnostics
company based in Paris (France), New Haven (Connecticut, USA) and
Milan (Italy) specialized in the early and accurate detection of
cancer. The company develops, produces and markets the proprietary
Ikoniscope20® platform, a fully-automated solution designed to
deliver accurate and reliable detection and analysis of rare and
very rare cells. Ikonisys has received FDA clearance for several
automated diagnostic applications, which are also marketed in
Europe under CE certification. Through its breakthrough
fluorescence microscopy platform, the company continues to develop
a stream of new tests, including liquid biopsy tests based on
Circulating Tumor Cells (CTC).
For further information, please go to www.Ikonisys.com.
View source
version on businesswire.com: https://www.businesswire.com/news/home/20231009201306/en/
Ikonisys Alessandro Mauri CFO investors@ikonisys.com
NewCap Aurélie Manavarere/Louis-Victor Delouvrier
Investor Relations Ikonisys@newcap.eu +33 (0)1 44 71 94 94
NewCap Nicolas Merigeau Media Relations
Ikonisys@newcap.eu +33 (0)1 44 71 94 98
Ikonisys (EU:ALIKO)
Graphique Historique de l'Action
De Mar 2024 à Avr 2024
Ikonisys (EU:ALIKO)
Graphique Historique de l'Action
De Avr 2023 à Avr 2024
